PB1864: BRUIN CLL-321: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB VS INVESTIGATOR’S CHOICE OF IDELALISIB+RITUXIMAB OR BENDAMUSTINE+RITUXIMAB IN BTKI PRETREATED CLL/SLL... by J. P. Sharman, W. Jurczak, C. C. Coombs, M. Hill, D. Wang, N. C. Ku, A. Guntur, S. Shahda, C. C. Leow, P. Ghia, A. R. Mato

Get full text

P1156: MAGNIFY PHASE 3B STUDY OF LENALIDOMIDE + RITUXIMAB (R2) FOLLOWED BY MAINTENANCE IN RELAPSED/REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA: COMPLETE INDUCTION PHASE ANALYSIS by F. Lansigan, D. J. Andorsky, M. Coleman, A. Yacoub, J. M. Melear, S. R. Fanning, K. S. Kolibaba, C. Reynolds, G. S. Nowakowski, M. Gharibo, J. R. Ahn, J. Li, M. J. Rummel, J. P. Sharman

Get full text

PB1890: ZANUBRUTINIB IN ACALABRUTINIB-INTOLERANT PATIENTS (PTS) WITH B-CELL MALIGNANCIES by M. Shadman, I. W. Flinn, E. C. Kingsley, B. Freeman, M. Y. Levy, J. Cultrera, C. M. Farber, A. Chaudhry, R. Porter, R. Crescenzo, A. Idoine, X. Zhang, A. Cohen, K. By, J. Huang, J. P. Sharman

Get full text

P1100: BRUIN MCL-321: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB VS INVESTIGATOR CHOICE OF BTK INHIBITOR IN PATIENTS WITH PREVIOUSLY TREATED, BTK INHIBITOR NAÏVE MCL (... by T. A. Eyre, N. N. Shah, S. Le Gouill, M. Dreyling, E. Vandenberghe, W. Jurczak, Y. Wang, C. Y. Cheah, M. Gandhi, C. Chay, J. P. Sharman, D. J. Andorsky, M. Yin, M. Balbas, J. Kherani, M. L. Wang

Get full text

P1192: ASIA SUBPOPULATION ANALYSIS FROM THE PHASE III POLARIX TRIAL by Y. Song, J. Jin, H. Tilly, H. Zhang, J. Cao, J. Feng, L. Zhang, S. Rai, H. Goto, Y. Terui, W. S. Kim, H.-J. Shin, J.-P. Gau, C.-H. Tsai, J. P. Sharman, L. Bu, J. Hirata, C. Lee, K. Izutsu, J. Zhu

Get full text

P666: ACALABRUTINIB ± OBINUTUZUMAB VS OBINUTUZUMAB + CHLORAMBUCIL IN TREATMENT-NAIVE CHRONIC LYMPHOCYTIC LEUKEMIA: 5-YEAR FOLLOW-UP OF ELEVATE-TN by J. P. Sharman, M. Egyed, W. Jurczak, A. Skarbnik, K. Patel, I. W. Flinn, M. Kamdar, T. Munir, R. Walewska, L. M. Fogliatto, Y. Herishanu, V. Banerji, G. Follows, P. Walker, K. Karlsson, P. Ghia, A. Janssens, F. Cymbalista, E. Ferrant, W. G. Wierda, V. Munugalavadla, T. Yu, M. H. Wang, J. A. Woyach

Get full text

P1101: PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REVERSIBLE) BTK INHIBITOR IN PREVIOUSLY TREATED MANTLE CELL LYMPHOMA: UPDATED RESULTS FROM THE PHASE 1/2 BRUIN STUDY by T. A. Eyre, M. L. Wang, N. N. Shah, A. J. Alencar, J. N. Gerson, M. R. Patel, B. Fakhri, E. Vandenberghe, W. Jurczak, X. N. Tan, K. L. Lewis, T. Fenske, Y. Wang, C. C. Coombs, I. Flinn, D. Lewis, S. Le Gouill, M. Gandhi, C. Chay, M. L. Palomba, J. A. Woyach, J. M. Pagel, N. Lamanna, J. P. Sharman, D. J. Andorsky, J. B. Cohen, M. A. Barve, P. Ghia, M. Yin, P. L. Zinzani, C. Ujjani, Y. Koh, K. Izutsu, E. Lech-Maranda, J. Kherani, C. Tam, S. Sundaram, B. Nair, D. E. Tsai, M. Balbas, A. R. Mato, C. Y. Cheah

Get full text